2024 ESC Guidelines for the management of peripheral arterial and aortic diseases: Developed by the task force on the management of peripheral arterial and aortic …

L Mazzolai, G Teixido-Tura, S Lanzi, V Boc… - European heart …, 2024 - academic.oup.com
• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Epidemiology of peripheral artery disease and polyvascular disease

AW Aday, K Matsushita - Circulation research, 2021 - ahajournals.org
Atherosclerotic lower extremity peripheral artery disease (PAD) is increasingly recognized
as an important cause of cardiovascular morbidity and mortality that affects> 230 million …

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of …

G Mancia, R Kreutz, M Brunström, M Burnier… - Journal of …, 2023 - journals.lww.com
Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici
(Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luıs Bronze (Portugal), John …

2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS guideline for the management of lower extremity peripheral artery disease: a report of the …

HL Gornik, HD Aronow, PP Goodney, S Arya… - Journal of the American …, 2024 - jacc.org
Abstract Aim The “2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS
Guideline for the Management of Lower Extremity Peripheral Artery Disease” provides …

Diagnosis and treatment of acute coronary syndromes: a review

DL Bhatt, RD Lopes, RA Harrington - Jama, 2022 - jamanetwork.com
Importance Acute coronary syndromes (ACS) are characterized by a sudden reduction in
blood supply to the heart and include ST-segment elevation myocardial infarction (STEMI) …

Sotagliflozin in patients with diabetes and recent worsening heart failure

DL Bhatt, M Szarek, PG Steg, CP Cannon… - New England journal …, 2021 - Mass Medical Soc
Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of
hospitalization for heart failure or death from cardiovascular causes among patients with …

Sotagliflozin in patients with diabetes and chronic kidney disease

DL Bhatt, M Szarek, B Pitt, CP Cannon… - … England Journal of …, 2021 - Mass Medical Soc
Background The efficacy and safety of sodium–glucose cotransporter 2 inhibitors such as
sotagliflozin in preventing cardiovascular events in patients with diabetes with chronic …

Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2022

T Okamura, K Tsukamoto, H Arai, Y Fujioka… - … of atherosclerosis and …, 2024 - jstage.jst.go.jp
In Japan, a super-aged society, deaths from atherosclerotic cardiovascular disease
(ASCVD), especially cardiac diseases including coronary artery disease (CAD) such as …

Burden of coronary artery disease and peripheral artery disease: a literature review

R Bauersachs, U Zeymer, JB Brière… - Cardiovascular …, 2019 - Wiley Online Library
Background. Atherothrombotic disease, including coronary artery disease (CAD) and
peripheral artery disease (PAD), can lead to cardiovascular (CV) events, such as myocardial …

World heart federation cholesterol roadmap 2022

KK Ray, BA Ference, T Séverin, D Blom… - Global …, 2022 - pmc.ncbi.nlm.nih.gov
Background: Atherosclerotic cardiovascular diseases (ASCVD) including myocardial
infarction, stroke and peripheral arterial disease continue to be major causes of premature …